A literature review published in JMCP found mixed evidence regarding the use of pharmacogenomic testing to guide cancer treatment. Prioritization of clinically relevant drug-gene associations is critical in determining which tests are beneficial.
Payer reimbursement pressures are leading to radical changes in the oncology treatment, but there is a need for improved guidance for providers in assessing drug value, according to an article in JMCP.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments to the Department of Health and Human Services (HHS) Office of Civil Rights (OCR) in response to its Request for Information on Modifying HIPAA Rules to Improve Coordinated Care [HHS-OCR-0945-AA00].
On February 12, 2019, AMCP provide comments to the HHS OCR in response to its Request for Information on Modifying HIPAA Rules to Improve Coordinated Care. AMCP shared its support of HIPAA modernization, specifically as it relates to aligning 42 CFR Part 2 requirements with HIPAA.